Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRESTIGE: Pemafibrate add-on vs statin dose doubling in type 2 diabetes with hypertriglyceridemia
jRCTs031190232Completed
- Sponsor
- Kowa Company, Ltd.
- Start
- Mar 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised trial of pemafibrate in type 2 diabetes mellitus (T2DM), hypertriglyceridemia and dyslipidemia (2 arms), sponsored by Kowa Company, Ltd. Primary endpoint: sd LDL-C reduction rate. Started Mar 2020; status: completed.
02
Drugs
pemafibrate
03
Conditions
type 2 diabetes mellitus (T2DM)hypertriglyceridemiadyslipidemia
Beyond the preview
Go deeper on jRCTs031190232.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031190232.